Literature DB >> 7983951

Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome.

H R Andersen1, L Thuesen, J P Bagger, T Vesterlund, P E Thomsen.   

Abstract

In patients with sick-sinus syndrome, single-chamber atrial pacing has been reported, in retrospective studies, to be associated with lower frequencies of atrial fibrillation, thromboembolism, heart failure, and mortality than ventricular pacing; although single-chamber ventricular pacing is most commonly used. We did a prospective randomised trial in 225 consecutive patients (142 women, 83 men; mean age 76 years) with the sick-sinus syndrome, randomised to atrial (n = 110) or ventricular (n = 115) pacing and followed for up to 5 years (mean 40 [SD 18] months). During follow-up, the frequency of atrial fibrillation was higher in the ventricular group, except at the first follow-up at 3 months. Thromboembolic events (stroke or peripheral arterial embolus) occurred in 20 patients in the ventricular group and in 6 patients in the atrial group (p = 0.0083). 25 patients died in the ventricular group compared with 21 in the atrial group (p = 0.74). Heart failure estimated by the New York Heart Association classification and by the daily doses of diuretics did not differ between the two groups. Atrioventricular block occurred in 2 patients in the atrial group. Patients with sick-sinus syndrome should be treated with atrial pacing rather than ventricular pacing because atrial pacing is associated with lower frequencies of atrial fibrillation, thromboembolic complications, and a low risk of atrioventricular block.

Entities:  

Mesh:

Year:  1994        PMID: 7983951     DOI: 10.1016/s0140-6736(94)90347-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  62 in total

Review 1.  Developing clinical indication for multisite pacing.

Authors:  L Kappenberger; X Lyon; N Cox; G Girod; J Schlaepfer
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

Review 2.  New devices and hybrid therapies and new devices for treatment of atrial fibrillation.

Authors:  R B Krol; S Saksena; A Prakash
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

Review 3.  Update in internal medicine.

Authors:  F López-Jiménez; M Brito; Y W Aude; P Scheinberg; M Kaplan; D A Dixon; N Schneiderman; J F Trejo; L H López-Salazar; E J Ramírez-Barba; R Kalil; C Ortiz; J Goyos; A Buenaño; S Kottiech; G A Lamas
Journal:  Arch Med Res       Date:  2000 Jul-Aug       Impact factor: 2.235

Review 4.  Endocavitary treatment of atrial fibrillation.

Authors:  S B Olsson; E I Hertervig; O Kongstad; C Meurling; S Yuan
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 5.  Clinical trials in pacing for bradyarrhythmias.

Authors:  Richard Sutton
Journal:  J Interv Card Electrophysiol       Date:  2003-10       Impact factor: 1.900

Review 6.  Pacing in prevention of atrial fibrillation: the PIPAF studies.

Authors:  F Anselme; N Saoudi; A Cribier
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

7.  Prevalence and clinical implications of atrial fibrillation episodes detected by pacemaker in patients with sick sinus syndrome.

Authors:  H F Tse; C P Lau
Journal:  Heart       Date:  2005-03       Impact factor: 5.994

8.  [Guidelines for heart pacemaker therapy].

Authors:  B Lemke; B Nowak; D Pfeiffer
Journal:  Z Kardiol       Date:  2005-10

Review 9.  [Modern pacing therapy].

Authors:  N Klein; M Klein; A Salameh; D Pfeiffer
Journal:  Internist (Berl)       Date:  2006-10       Impact factor: 0.743

10.  Future easy and physiological cardiac pacing.

Authors:  Eraldo Occhetta; Miriam Bortnik; Paolo Marino
Journal:  World J Cardiol       Date:  2011-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.